Amarin Corp. plc
Amarin posts quarterly loss of $0.10 per share
Published in Pharma Law Weekly, March 21st, 2006
For the quarter ended December 31, 2005 Amarin reported a net loss of $5.2 million or 10 cents per American Depositary Share (ADS), compared with a net loss of $4.8 million or 13 cents per ADS in the quarter ended December 31, 2004. The net loss for the quarter primarily reflects Amarin's substantial investment in research and development and intellectual property offset by license fee revenue and a reduction in selling, general and administrative costs.
For the year ended December 31, 2005, Amarin reported a net loss of $18.7 million or...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
Source: Pharma Law Weekly (2006-03-21)
More Articles from Pharma Law Weekly
- Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals reports loss of $0.56 per share - Arachnova Therapeutics Limited
Arachnova portfolio strengthened with new patents for MCI-225 - AstraZeneca
Economic impact of acute ischemic stroke highlighted in new study - Baylor College of Medicine, Houston
Ethics of signing on to the medical-industrial complex are examined - California Coalition for Compassionate Access
California group launched to support medical marijuana - Cipher Pharmaceuticals, Inc.
CIP-Fenofibrate approval from Health Canada received by Cipher - More from this issue of Pharma Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
